How Much Can Abbott’s Stock Move In 2018?
2017 was a good year for Abbott (NYSE:ABT), as the company’s stock gained nearly 50%. The momentum continued in the first month of 2018 as well, as better than expected Q4’17 results triggered the stock movement. It appears that Abbott’s acquisitions of St Jude Medical and Alere, which were earlier seen as risky bets, are paying off. Does this mean that the stock can move further this year? Our base case analysis suggests that the potential certainly exists. We have created an interactive valuation calculator dashboard using Trefis’ interactive technology where you can modify inputs such as P/E multiple and fundamentals determining Abbott’s 2018 earnings (non-GAAP net income). If you have a different view, you can create your own scenario and come up with your own price estimate for Abbott.
See More at Trefis | View Interactive Institutional Research (Powered by Trefis)
- What’s Next For Abbott Stock After A 6% Rise This Year?
- Is Abbott Stock Undervalued At $95?
- Which Is A Better Pick – Abbott Stock Or Amgen?
- Is Abbott Stock A Better Healthcare Pick Over Thermo Fisher Scientific?
- Lower Testing Demand To Weigh On Abbott’s Q2?
- Will Abbott Stock Rebound To Its 2022 Highs?